A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences–and so preventing mutations–are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability.
SOURCE: Latest Science News — ScienceDaily – Read entire story here.
Related Posts
New study used 3D-printed sensors to measure spinal cord malformations in embryos
The i3D bioprinting with accurately determined position, geometry and stiffness. Credit: Nature Materials (2024). DOI: […]
Ice bucket campaign raises $1m for Australian MND research
A social media campaign that saw people across the world doused with ice-cold water raises $1 million for an Australian team researching motor neurone disease.
Stem cell therapy for inherited skin blistering
Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.